NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

EXEL

Exelixis Inc

Jun 30 • 04:00PM ET

44.08

Dollar change +0.41
Percentage change 0.93	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VXF VBK XBI XMHQ MDY IBB IJK

Index	-	P/E	20.00	EPS (ttm)	2.20	Insider Own	3.23%	Shs Outstand	275.03M	Perf Week	1.63%
Market Cap	12.02B	Forward P/E	13.87	EPS next Y	3.18	Insider Trans	-7.96%	Shs Float	263.89M	Perf Month	3.46%
Enterprise Value	11.18B	PEG	0.62	EPS next Q	0.64	Inst Own	92.62%	Short Float	7.72%	Perf Quarter	20.10%
Income	643.57M	P/S	5.23	EPS this Y	51.04%	Inst Trans	0.65%	Short Ratio	6.32	Perf Half Y	30.32%
Sales	2.30B	P/B	5.69	EPS next Y	19.53%	ROA	22.82%	Short Interest	20.39M	Perf YTD	32.36%
Book/sh	7.75	P/C	11.65	EPS next 5Y	32.33%	ROE	30.22%	52W High	49.62 -11.17%	Perf Year	96.94%
Cash/sh	3.78	P/FCF	14.64	EPS past 3/5Y	34.91% 11.55%	ROIC	27.76%	52W Low	21.82 101.99%	Perf 3Y	106.63%
Dividend Est.	-	EV/EBITDA	13.24	Sales past 3/5Y	14.76% 17.51%	Gross Margin	96.78%	Volatility	3.71% 3.24%	Perf 5Y	84.41%
Dividend TTM	-	EV/Sales	4.86	EPS Y/Y TTM	244.87%	Oper. Margin	35.43%	ATR (14)	1.71	Perf 10Y	1021.50%
Dividend Ex-Date	-	Quick Ratio	3.44	Sales Y/Y TTM	24.49%	Profit Margin	27.99%	RSI (14)	57.96	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	353.64%	SMA20	3.57%	Beta	0.28	Target Price	44.47
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	30.62%	SMA50	7.45%	Rel Volume	1.07	Prev Close	43.67
Employees	1147	LT Debt/Eq	0.09	Earnings	May 13 AMC	SMA200	24.79%	Avg Volume	3.23M	Price	44.08
IPO	Apr 11, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	73.14% 11.18%	Trades		Volume	3,433,194	Change	0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight	$60
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Show Previous Ratings

Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
10:32AM	Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold (Zacks)
Jun-28-25 06:35AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
Jun-27-25 01:14PM	Incyte Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
08:48AM	Loading…
08:48AM	3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns (Zacks)
Jun-26-25 03:24PM	Stephens Upgrades Exelixis (EXEL) Stock, Raises PT (Insider Monkey)
Jun-25-25 12:45PM	3 Reasons Growth Investors Will Love Exelixis (EXEL) (Zacks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
05:50AM	The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis (Zacks)
01:30AM	23 Stocks That Score High on What Counts in the 2025 Market (Barrons.com)
Jun-24-25 12:20PM	MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal (Zacks) +5.42%
12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
09:40AM	Loading…
09:40AM	EXEL Stock Rises on Positive Data From Colorectal Cancer Study (Zacks)
09:15AM	Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out? (Zacks)
07:29AM	Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2 (Zacks)
Jun-23-25 04:27PM	Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug (Investor's Business Daily) +7.43%
12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
09:38AM	Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug (Investor's Business Daily)
05:04AM	Premarket movers: Tesla, Northern Trust, Exelixis (MarketWatch)
Jun-22-25 05:00PM	Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer (Business Wire)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks)
06:54AM	Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jun-17-25 11:40AM	EXEL or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
04:51AM	Loading…
Jun-13-25 04:51AM	Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis (Zacks)
Jun-12-25 03:00PM	4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio (Zacks)
11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
04:00AM	Can reputational pull save biotech from pharmas image problem? (Pharma Voice)
Jun-11-25 09:01AM	3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL) (Zacks)
06:35AM	CPI Inflation Set To Pick Up Amid Trump Tariffs (Live Coverage) (Investor's Business Daily)
Jun-10-25 06:07PM	Stock Market Extends Gains, But Rotation Hits Growth Stocks Hard; Chip Stocks Buoy Nasdaq (Investor's Business Daily)
Jun-09-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) (Zacks)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
12:00PM	Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice (Zacks)
Jun-05-25 09:37PM	BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution (Insider Monkey)
Jun-04-25 10:18AM	Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? (Zacks)
09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
06:57AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
Jun-02-25 09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
May-30-25 09:35AM	Top 4 Value Stocks With Impressive PEG Ratios to Buy Now (Zacks)
08:00AM	2 Top Stocks to Buy With Less Than $100 (Motley Fool)
May-29-25 05:38PM	Exelixis Catapults To Record High After Obliterating First-Quarter Expectations (Investor's Business Daily)
May-28-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
May-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) (Zacks)
12:20PM	Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? (Zacks)
12:00PM	Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:40AM	EXEL vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
06:25AM	Product Performance, Big Money Lift Exelixis (FX Empire)
May-22-25 05:17PM	Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 (Business Wire)
04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June (Business Wire)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
12:00PM	Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
09:42AM	Company News for May 15, 2025 (Zacks)
May-14-25 07:56PM	Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday (Insider Monkey) +20.84%
04:42PM	These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
03:05PM	These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
11:33AM	Why Exelixis Stock Is Skyrocketing Today (Motley Fool)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
08:40AM	Q1 2025 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-13-25 06:06PM	Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors (Business Wire)
06:00PM	Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:23PM	Exelixis: Q1 Earnings Snapshot (Associated Press Finance)
04:19PM	Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations (Investor's Business Daily)
04:07PM	Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
May-12-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-11-25 04:52PM	Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:15AM	Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
May-07-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May (Business Wire)
May-03-25 02:47PM	Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy (Insider Monkey)
May-02-25 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Apr-29-25 04:05PM	Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (Business Wire)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-26-25 08:00AM	MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points (Investor's Business Daily)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
Apr-24-25 10:02AM	Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-16-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now? (Zacks)
Apr-14-25 06:20AM	Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar? (Zacks)
Apr-11-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eckhardt Sue Gail	Director	Jun 02 '25	Sale	42.74	18,838	805,140	21,380	Jun 04 07:57 PM
WYSZOMIERSKI JACK L	Director	Jun 03 '25	Sale	43.09	7,535	324,683	358,882	Jun 04 07:57 PM
JACK L WYSZOMIERSKI	Director	Jun 03 '25	Proposed Sale	43.09	7,535	324,658		Jun 03 04:04 PM
Eckhardt Sue Gail	Director	Jun 02 '25	Proposed Sale	43.54	18,838	820,206		Jun 02 04:12 PM
Haley Patrick J.	EVP, Commercial	May 20 '25	Sale	44.06	34,387	1,515,091	412,072	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Sale	44.29	4,544	201,254	32,470	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Proposed Sale	44.29	4,544	201,259		May 21 04:08 PM
PATRICK JOSEPH HALEY	Officer	May 20 '25	Proposed Sale	44.06	34,387	1,514,998		May 20 05:23 PM
POSTE GEORGE	Director	May 16 '25	Option Exercise	19.77	20,634	407,934	189,654	May 16 08:58 PM
POSTE GEORGE	Director	May 16 '25	Sale	45.99	20,634	948,958	169,020	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Option Exercise	18.80	100,000	1,880,000	1,067,842	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Sale	46.00	100,000	4,600,000	967,842	May 16 08:58 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Option Exercise	20.09	36,508	733,351	1,300,050	May 16 08:57 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Sale	44.35	36,508	1,619,130	1,279,416	May 16 08:57 PM
MORRISSEY MICHAEL	President and CEO	May 14 '25	Option Exercise	18.80	308,365	5,797,262	1,931,374	May 16 08:57 PM
Hessekiel Jeffrey	EVP & General Counsel	May 15 '25	Sale	46.18	25,000	1,154,500	693,396	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Option Exercise	18.80	116,383	2,188,000	562,842	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Sale	47.96	126,383	6,061,703	446,459	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 14 '25	Sale	42.68	10,000	426,800	491,164	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Option Exercise	21.75	40,000	870,000	538,169	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Sale	45.47	72,776	3,309,125	465,393	May 16 08:57 PM
AMY PETERSON	Officer	May 16 '25	Proposed Sale	46.26	72,776	3,366,618		May 16 04:11 PM
CHRISTOPHER J SENNER	Officer	May 16 '25	Proposed Sale	46.00	100,000	4,600,000		May 16 04:09 PM
GEORGE POSTE	Director	May 16 '25	Proposed Sale	45.99	20,634	948,958		May 16 04:09 PM
STELIOS PAPADOPOULOS	Director	May 15 '25	Proposed Sale	44.35	36,508	1,619,130		May 15 06:00 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	48.05	116,383	5,592,739		May 15 05:09 PM
JEFFREY J HESSEKIEL	Officer	May 15 '25	Proposed Sale	46.18	25,000	1,154,610		May 15 04:29 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	46.95	10,000	469,500		May 15 04:05 PM
PATRICK JOSEPH HALEY	Officer	May 14 '25	Proposed Sale	42.68	10,000	426,800		May 14 04:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	May 01 '25	Sale	39.00	1,508	58,812	693,181	May 05 07:12 PM
DANA T AFTAB	Officer	May 01 '25	Proposed Sale	39.00	1,508	58,812		May 01 04:02 PM
Haley Patrick J.	EVP, Commercial	Mar 03 '25	Sale	38.80	10,000	388,000	341,028	Mar 05 08:47 PM
PATRICK JOSEPH HALEY	Officer	Mar 03 '25	Proposed Sale	38.80	10,000	388,000		Mar 03 04:18 PM
Smith Julie	Director	Feb 27 '25	Option Exercise	20.19	54,514	1,100,494	65,292	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Option Exercise	19.77	19,294	381,442	30,072	Feb 28 08:35 PM
Smith Julie	Director	Feb 27 '25	Sale	38.13	54,514	2,078,619	10,778	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Sale	37.62	19,294	725,840	10,778	Feb 28 08:35 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Option Exercise	20.50	15,874	325,417	365,373	Feb 28 08:34 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Sale	37.80	8,768	331,430	356,605	Feb 28 08:34 PM
JACK L WYSZOMIERSKI	Director	Feb 28 '25	Proposed Sale	37.80	8,768	331,394		Feb 28 04:05 PM
Smith Julie	Director	Feb 27 '25	Proposed Sale	37.13	73,808	2,740,491		Feb 27 05:12 PM
Haley Patrick J.	EVP, Commercial	Feb 24 '25	Sale	36.98	52,636	1,946,479	303,310	Feb 26 08:01 PM
Oliver Bob	Director	Feb 25 '25	Option Exercise	19.28	15,147	292,034	52,161	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Sale	37.25	18,647	694,601	33,514	Feb 26 08:00 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 24 '25	Sale	36.75	26,987	991,772	511,908	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Option Exercise	18.80	29,314	551,103	808,921	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Sale	36.14	29,314	1,059,408	779,607	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Proposed Sale	37.25	18,647	694,601		Feb 25 05:05 PM
Haley Patrick J.	Officer	Feb 24 '25	Proposed Sale	36.84	52,636	1,939,213		Feb 24 06:02 PM
Aftab Dana	Officer	Feb 24 '25	Proposed Sale	36.75	26,987	991,772		Feb 24 05:55 PM
Senner Christopher J.	Officer	Feb 24 '25	Proposed Sale	36.14	29,314	1,059,370		Feb 24 03:34 PM
Beckerle Mary C	Director	Feb 14 '25	Option Exercise	23.24	8,354	194,147	42,616	Feb 19 08:32 PM
Beckerle Mary C	Director	Feb 14 '25	Sale	34.88	12,210	425,878	30,406	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Option Exercise	20.50	15,874	325,417	184,894	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Sale	34.74	15,874	551,463	169,020	Feb 19 08:32 PM
Freire Maria C	Director	Feb 14 '25	Option Exercise	21.52	44,114	949,521	135,121	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Sale	34.94	44,114	1,541,343	91,007	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Option Exercise	23.24	7,712	179,227	41,974	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Sale	35.02	11,568	405,111	30,406	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Proposed Sale	34.94	44,114	1,541,207		Feb 14 05:59 PM
Beckerle Mary C	Director	Feb 14 '25	Proposed Sale	34.88	12,210	425,865		Feb 14 05:40 PM
POSTE GEORGE	Director	Feb 14 '25	Proposed Sale	34.74	15,874	551,431		Feb 14 05:36 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Proposed Sale	34.37	11,568	397,592		Feb 14 04:20 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Option Exercise	18.80	96,986	1,823,337	595,931	Nov 07 07:44 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Sale	35.00	96,986	3,394,510	498,945	Nov 07 07:44 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 01 '24	Sale	34.13	50,000	1,706,500	530,325	Nov 05 07:05 PM
POSTE GEORGE	Director	Nov 01 '24	Sale	34.00	30,000	1,020,000	169,020	Nov 05 07:04 PM
DANA T AFTAB	Officer	Nov 05 '24	Proposed Sale	35.00	96,986	3,394,510		Nov 05 04:23 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Oct 30 '24	Sale	31.40	1,162	36,487	498,945	Nov 01 06:43 PM
POSTE GEORGE	Director	Nov 01 '24	Proposed Sale	34.00	30,000	1,020,112		Nov 01 04:54 PM
JEFFREY J HESSEKIEL	Officer	Nov 01 '24	Proposed Sale	33.20	25,000	830,000		Nov 01 04:47 PM
Hessekiel Jeffrey	EVP & General Counsel	Oct 28 '24	Sale	28.39	25,000	709,750	580,325	Oct 30 06:04 PM
DANA T AFTAB	Officer	Oct 30 '24	Proposed Sale	31.40	1,162	36,487		Oct 30 04:10 PM
Haley Patrick J.	EVP, Commercial	Oct 02 '24	Option Exercise	24.41	100,000	2,441,000	441,036	Oct 03 09:22 PM
MORRISSEY MICHAEL	President and CEO	Oct 01 '24	Option Exercise	24.41	480,000	11,716,800	1,444,384	Oct 03 09:22 PM
Hessekiel Jeffrey	EVP & General Counsel	Sep 23 '24	Sale	26.38	25,000	659,500	605,325	Sep 25 07:32 PM
JEFFREY J HESSEKIEL	Officer	Sep 23 '24	Proposed Sale	26.42	75,000	1,981,500		Sep 23 04:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Option Exercise	24.41	20,000	488,200	650,325	Aug 28 07:07 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Sale	25.79	20,000	515,800	630,325	Aug 28 07:07 PM
Freire Maria C	Director	Aug 14 '24	Sale	26.56	8,250	219,120	91,007	Aug 16 07:35 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 12 '24	Sale	27.06	20,883	565,094	500,107	Aug 14 07:12 PM
MARIA C FREIRE	Director	Aug 14 '24	Proposed Sale	26.56	8,250	219,122		Aug 14 05:01 PM
POSTE GEORGE	Director	Aug 08 '24	Sale	26.89	33,725	906,865	199,020	Aug 12 07:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Option Exercise	24.41	95,000	2,318,950	615,990	Aug 09 07:32 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Sale	25.00	95,000	2,375,000	520,990	Aug 09 07:32 PM
Haley Patrick J.	EVP, Commercial	Aug 07 '24	Sale	25.50	14,000	357,000	341,036	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Option Exercise	24.41	80,000	1,952,800	710,325	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Sale	25.97	80,000	2,077,600	630,325	Aug 09 07:32 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Option Exercise	24.41	125,000	3,051,250	846,680	Aug 09 07:31 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Sale	27.19	125,000	3,398,750	721,680	Aug 09 07:31 PM
Senner Christopher J.	Officer	Aug 09 '24	Proposed Sale	27.17	125,000	3,396,250		Aug 09 05:20 PM
Aftab Dana	Officer	Aug 09 '24	Proposed Sale	27.25	20,883	569,062		Aug 09 05:18 PM

Dollar change 0.00
Percentage change 0.00	%

RGLS Regulus Therapeutics Inc daily Stock Chart

Peers: IONS ARWR SRPT MRNA RNA ALNY SGMO PRQR WVE BBIO

| Held by: VTI VXF VTWO VTWV VTWG VTHR

Index	RUT	P/E	-	EPS (ttm)	-0.73	Insider Own	17.19%	Shs Outstand	66.28M	Perf Week	-0.73%
Market Cap	564.92M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.36%	Shs Float	57.33M	Perf Month	3.16%
Enterprise Value	501.49M	PEG	-	EPS next Q	-	Inst Own	68.25%	Short Float	3.07%	Perf Quarter	466.67%
Income	-47.52M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.66	Perf Half Y	440.40%
Sales	0.00M	P/B	7.84	EPS next Y	-	ROA	-50.30%	Short Interest	1.76M	Perf YTD	416.46%
Book/sh	1.04	P/C	8.63	EPS next 5Y	-	ROE	-53.82%	52W High	8.35 -2.22%	Perf Year	223.81%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	36.71% 40.21%	ROIC	-67.48%	52W Low	0.83 883.01%	Perf 3Y	236.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.32% 1.55%	Perf 5Y	-7.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.19%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-99.36%
Dividend Ex-Date	-	Quick Ratio	15.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.62	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.52	EPS Q/Q	50.58%	SMA20	0.97%	Beta	0.35	Target Price	7.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	22.77%	Rel Volume	0.00	Prev Close	8.16
Employees	34	LT Debt/Eq	0.02	Earnings	May 08 AMC	SMA200	195.51%	Avg Volume	2.66M	Price	8.16
IPO	Oct 04, 2012	Option/Short	Yes / No	EPS/Sales Surpr.	38.78% -	Trades		Volume	9,342,413	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$3 → $6
Aug-02-24	Initiated	Oppenheimer	Outperform	$7
Mar-18-24	Initiated	Leerink Partners	Outperform	$6
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral	$1
Jan-05-18	Initiated	Leerink Partners	Outperform	$2
Jun-13-17	Reiterated	Chardan Capital Markets	Buy	$5 → $2.50
Mar-06-17	Reiterated	Wedbush	Outperform	$8 → $6
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-30-17	Downgrade	Needham	Buy → Hold
Dec-07-16	Reiterated	Chardan Capital Markets	Buy	$12 → $5
Nov-02-16	Reiterated	Needham	Buy	$10 → $9
Jul-25-16	Reiterated	Chardan Capital Markets	Buy	$14.50 → $12
Jun-28-16	Reiterated	Needham	Buy	$25 → $10
Jun-28-16	Reiterated	FBR Capital	Outperform	$30 → $9
Jun-28-16	Reiterated	Chardan Capital Markets	Buy	$20 → $13.50
Jun-07-16	Reiterated	Chardan Capital Markets	Buy	$15 → $20
Apr-13-16	Initiated	Chardan Capital Markets	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform	$30

Show Previous Ratings

Jun-26-25 05:25AM	Novartis concludes Regulus Therapeutics acquisition (Pharmaceutical Technology)
Jun-25-25 09:13AM	Novartis completes acquisition of Regulus Therapeutics (GlobeNewswire)
01:00AM	Novartis announces expiration of Regulus Therapeutics tender offer (GlobeNewswire)
May-08-25 04:49PM	Regulus: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates (PR Newswire)
09:39AM	Loading…
May-02-25 09:39AM	Novartis to buy Regulus Therapeutics for as much as $1.7 billion (LA Times)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
07:26AM	Novartis to strengthen renal disease portfolio with Regulus (Pharmaceutical Technology)
Apr-30-25 04:30PM	Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (Seeking Alpha) +136.80%
08:15AM	Novartis to acquire Regulus in deal for kidney disease drug (BioPharma Dive)
07:50AM	Novartis to Acquire Regulus in $1.7 Billion Deal (The Wall Street Journal)
07:24AM	Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal (Reuters)
07:00AM	Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
Apr-24-25 09:55AM	Should You Buy Regulus (RGLS) After Golden Cross? (Zacks) +9.80%
Apr-18-25 03:25PM	Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? (Insider Monkey)
08:00AM	Loading…
Apr-02-25 08:00AM	Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit (PR Newswire) +12.00%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha) +15.33%
Mar-27-25 07:00AM	Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +16.28%
Mar-19-25 12:00PM	What Makes Regulus (RGLS) a New Buy Stock (Zacks)
Mar-18-25 04:44AM	Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-13-25 04:18PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance) -6.76% +7.25%
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates (PR Newswire)
Mar-04-25 08:00AM	Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference (PR Newswire) +7.14%
Feb-21-25 03:42AM	Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently (Insider Monkey)
Feb-04-25 08:00AM	Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) +8.94%
Jan-29-25 12:48PM	Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data (GuruFocus.com) -17.09%
07:00AM	Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) (PR Newswire)
Nov-26-24 08:00AM	Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences (PR Newswire)
Nov-07-24 05:13PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates (PR Newswire)
06:01AM	Loading…
Oct-29-24 06:01AM	These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts (TipRanks) +7.33%
Oct-08-24 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -9.36%
Aug-28-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) -7.78%
Aug-08-24 05:19PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates (PR Newswire)
Aug-06-24 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-09-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire)
Jun-24-24 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -18.33%
Jun-04-24 08:00AM	Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes (PR Newswire)
May-16-24 08:00AM	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer (PR Newswire)
May-09-24 10:57PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
05:16PM	Regulus: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates (PR Newswire)
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace) -8.23%
May-06-24 08:00AM	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.30%
Apr-30-24 08:00AM	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series (PR Newswire) -8.73%
Mar-23-24 05:33AM	Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements (GuruFocus.com)
Mar-21-24 10:53PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.20%
04:22PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates (PR Newswire)
Mar-13-24 12:09PM	Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study (Zacks)
Mar-12-24 06:32AM	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity (PR Newswire) +71.01%
06:30AM	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jan-02-24 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Nov-22-23 08:00AM	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -5.11%
Nov-09-23 04:32PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance) -5.21%
04:05PM	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Nov-02-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +9.76%
Oct-19-23 08:00AM	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-20-23 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -20.61%
Sep-13-23 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +13.70%
Sep-05-23 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) +10.60%
Aug-24-23 07:33PM	Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap? (GuruFocus.com) +17.33% -6.25%
Aug-23-23 01:04PM	Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) +17.19%
08:00AM	Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 (PR Newswire)
Aug-08-23 04:43PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Aug-02-23 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-18-23 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference (PR Newswire)
Jun-27-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +6.72%
Jun-23-23 08:00AM	Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors (PR Newswire)
Jun-20-23 08:00AM	Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital (PR Newswire) -8.67%
Jun-12-23 08:00AM	Regulus Therapeutics Strengthens Research & Development Leadership (PR Newswire) +8.15%
May-16-23 08:00AM	Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.45%
May-11-23 04:18PM	Regulus: Q1 Earnings Snapshot (AP Finance) +15.33%
04:05PM	Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Apr-13-23 08:00AM	Regulus Therapeutics Announces $15 Million Private Placement of Equity (PR Newswire) +35.54%
Apr-12-23 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.24%
Mar-23-23 04:52PM	Regulus: Q4 Earnings Snapshot (AP Finance) -8.49%
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates (PR Newswire)
Feb-09-23 08:00AM	Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Jan-13-23 04:05PM	Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Jan-09-23 06:01AM	Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics (Benzinga)
Dec-12-22 08:00AM	Regulus Therapeutics Announces Resignation of Board Member (PR Newswire) +8.70%
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
08:00AM	Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations (PR Newswire)
Nov-10-22 04:05PM	Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Nov-03-22 08:00AM	Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -5.52%
Nov-02-22 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.07%
Sep-13-22 11:58AM	Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study (Zacks) +10.31%
Sep-12-22 11:14AM	Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease (Benzinga) +15.48%
08:00AM	Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-02-22 04:05PM	Regulus Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +5.19% +14.08%
Aug-11-22 04:10PM	Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Aug-04-22 08:00AM	Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) +14.09%
Jun-21-22 08:00AM	Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-13-22 08:00AM	Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-02-22 08:00AM	Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK (PR Newswire)
May-17-22 04:30PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.56%
07:00AM	7 Penny Stocks With 10x Potential This Year (InvestorPlace)

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Collier Kathryn J	Director	Jun 17 '25	Option Exercise	9.38	4,929	46,240	65,240	Jun 18 05:00 PM
Collier Kathryn J	Director	Jun 16 '25	Option Exercise	9.90	1,396	13,820	67,844	Jun 18 05:00 PM
Klassen Preston	President & Head of R & D	Jun 03 '25	Buy	7.99	12,000	95,852	48,055	Jun 04 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 30 '25	Buy	1.09	50,000	54,260	260,808	Jan 31 05:00 PM
BALTIMORE DAVID	Director	Jan 30 '25	Buy	1.06	19,610	20,787	22,169	Jan 31 05:00 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 13 '25	Sale	1.26	38,547	48,693	54,634	Jan 15 05:00 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 14 '25	Sale	1.26	5,088	6,427	49,546	Jan 15 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 13 '25	Sale	1.26	115,290	145,634	222,572	Jan 15 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 14 '25	Sale	1.26	11,764	14,860	210,808	Jan 15 05:00 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 13 '25	Sale	1.26	38,716	48,906	50,566	Jan 15 05:00 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 14 '25	Sale	1.26	5,088	6,427	45,478	Jan 15 05:00 PM
Klassen Preston	President & Head of R & D	Jan 13 '25	Sale	1.26	31,445	39,721	36,055	Jan 15 05:00 PM
Collier Kathryn J	Director	Jul 25 '24	Buy	1.82	4,000	7,280	6,740	Jul 29 04:18 PM

EXEL

Exelixis Inc

RGLS

Regulus Therapeutics Inc

Upgrade your FINVIZ experience